Table 4 Patient demographics and clinical features available for evaluation
Demographic data | |
Age | 54 ± 12.5 [24–88], IQR 16.3 |
Histological data | |
Receptor status ER (+/−) | negative (22), positive (133), NA (1) |
Receptor status PR (+/−) | negative (44), positive (110), NA (2) |
Receptor status HER2 (+/−) | negative (126), positive (16), NA (14) |
Subtype | basal (12), HER2 (9), luminal (131), NA (4) |
Molecular subtype | basal (12), HER2 (9), luminalA (113), luminalB (4), NA (18) |
Grade | 1 (11), 2 (102), 3 (41), NA (2) |
Lymphovascular space invasion (LVSI) (determined at surgery) | absent (107), present (42), NA (7) |
Nodal status (determined at surgery) | negative (99), positive (39), micrometastases (11), NA (7) |
Disease pathology (multiple conditions allowed per patient) | DCIS (47), IDC (95), ILC (62), LCIS (23) |
Miscellaneous diagnostic data | |
Number of recorded lesions * For some patients, clinical measurements recorded after therapy noted no residual tumour | 0* (7), 1 (133), 2 (14), 3 (2) |
Laterality | left (87), right (63), bilateral (6) |
Tumour size | (31 ± 24) [0–128] mm, IQR 26 mm |
Focality (largest tumour) | unifocal (126), bifocal (12), multifocal (17), NA (1) |
Type (largest tumour) | ductal (91), lobular (52), both (11), NA (2) |
Treatment | |
Surgery | Central excision (1), mastectomy (58), therapeutic mammoplasty (1), WLE (94), NA (2) |
Neoadjuvant chemoendocrine therapy | no (112), yes (43), NA (1) |
Survival data | |
Date of diagnosis | March 2007 – July 2014 |
Date of imaging | January 2012 – December 2013 |
Date of surgery | January 2012 – September 2019 |
Date of death or last follow up | August 2013 – August 2019 |
Status at last follow-up | alive (140), dead (16) |